Eisai Establishes Subsidiary in Mexico
Eisai Laboratorios, S. de R.L. de C.V. to Introduce Eisai's Medicines to People Living in Mexico

Woodcliff Lake, NJ, August 16, 2011 - Eisai Inc. and its parent company Eisai Co., Ltd. today announce the establishment of a subsidiary company in Mexico, which will be named Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico). As a direct subsidiary of Eisai Inc., Eisai Mexico will be based in Mexico City, the country's capital city.

The company's immediate focus will be on establishing an initial infrastructure to support its operations debut into the Mexican market. Eisai Mexico is the company's second subsidiary in Latin America, following the establishment of Eisai Participações Ltda. (Eisai Brazil) earlier this year.

"Eisai is very pleased to continue expansion into Latin America with our newest subsidiary, Eisai Mexico," said Hajime Shimizu, President, New Markets and ASEAN, Eisai Co., Ltd. "The establishment of this new company enables Eisai to introduce many of its products to people living in Mexico who currently do not have access to these medicines, and this is essential to Eisai's human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide."

Eisai Mexico's areas of commercial focus will include neurology, oncology and critical care.

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

Type Press Release

Date Released August 16, 2011

Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
* Required Fields